JNJ-64264681

N/A

Report date: 2024/03/04 10:41:17
NME

Base Information

Drug NameJNJ-64264681
Drug Alias NameJNJ-64264681JNJ-4681
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[16] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson IncJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A